Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $37.3 million.

  • Lyell Immunopharma's Operating Expenses fell 2625.89% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $342.9 million, marking a year-over-year increase of 5791.03%. This contributed to the annual value of $358.8 million for FY2024, which is 4518.85% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Operating Expenses of $37.3 million as of Q3 2025, which was down 2625.89% from $47.1 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Operating Expenses registered a high of $201.2 million during Q4 2024, and its lowest value of $37.3 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $65.5 million, with a median of $59.1 million in 2023.
  • In the last 5 years, Lyell Immunopharma's Operating Expenses plummeted by 3817.89% in 2021 and then surged by 23796.14% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Operating Expenses (Quarter) stood at $50.4 million in 2021, then increased by 25.44% to $63.2 million in 2022, then decreased by 5.78% to $59.5 million in 2023, then soared by 237.96% to $201.2 million in 2024, then crashed by 81.47% to $37.3 million in 2025.
  • Its last three reported values are $37.3 million in Q3 2025, $47.1 million for Q2 2025, and $57.4 million during Q1 2025.